Selegiline Patch for TRD: A PMHNP Prescribing Protocol

Most PMHNPs will write hundreds of SSRI prescriptions before they write a single MAOI. That habit has a cost. For patients who have failed two, three, or four antidepressants, the drug class with some of the strongest track records in atypical and treatment-resistant depression is often never offered.

The usual reason is fear: the cheese reaction, the interaction list, the washout math. The selegiline transdermal system, sold as EMSAM, removes the biggest of those barriers. At its starting and target dose of 6 mg/24 hours, the FDA label requires no tyramine diet at all.

The September 2026 issue of The Carlat Psychiatry Report reviewed fresh real-world data suggesting the patch deserves another look. In 117 patients with treatment-resistant depression, it beat tricyclics on effectiveness and had fewer side effect categories than both tricyclics and oral MAOIs.

This protocol covers who to choose, how to switch safely, how to dose, and what to watch for. The washout is where most of the risk sits, so most of the detail goes there.

Why the Patch Changes the MAOI Math

Oral MAOIs inhibit MAO-A in the gut wall and liver. That enzyme normally breaks down dietary tyramine. Block it, and a plate of aged cheese or cured salami can let tyramine reach the bloodstream and trigger a hypertensive reaction.

The patch skips that first pass. Selegiline goes through the skin straight into the bloodstream, so the brain gets enough drug to inhibit MAO-A and MAO-B while much of the gut’s MAO-A stays working at 6 mg. That is why the label drops the diet at 6 mg and brings it back at 9 and 12 mg, where enough drug reaches the gut to matter.

The newest effectiveness data comes from Kim and colleagues in the Journal of Affective Disorders (2025), summarized by Carlat. The study looked back at 117 patients with treatment-resistant depression at a university mood clinic who were treated with the patch, a flexibly dosed oral MAOI, or a tricyclic.

• Versus tricyclics: the patch improved CGI-S scores by 0.81 points more (p=0.016).
• Versus oral MAOIs: the patch improved CGI-S scores by 0.62 points less (p=0.035). The oral MAOI group was treated longer, which may explain part of that gap.
• Safety: no hypertensive crises and no serotonin syndrome in any group.
• Tolerability: fewer side effect categories than either comparator, with fewer cardiovascular effects than oral MAOIs but more skin reactions.

It was a retrospective chart review, not a randomized trial, so read it as a signal and not as proof. Still, it matches what clinicians already see in practice: the patch is a gentler way into the MAOI class.

Who Is a Good Candidate

The patch makes the most sense for adults with major depressive disorder who have failed at least two adequate antidepressant trials and who can reliably follow an interaction list. NIMH notes that many people with depression need more than one treatment attempt before they find one that works. Those patients are the ones who end up on your schedule.

Strong candidates

• Two or more failed SSRI or SNRI trials at adequate dose and duration.
• Atypical features such as heavy fatigue, oversleeping, increased appetite, or rejection sensitivity.
• Patients who can’t swallow pills or who struggle with GI side effects.
• Patients who would refuse an oral MAOI because of the diet.
• Patients who are organized, take few other medications, and have one prescriber and one pharmacy.

Hold off or think twice

• Children under 12 (contraindicated) and adolescents 12 to 17 (not recommended).
• Pheochromocytoma (contraindicated).
• Chronic pain managed with tramadol, methadone, or meperidine, or regular cough-medicine use with dextromethorphan.
• Bipolar depression without a mood stabilizer, since any antidepressant can trigger a switch.
• Active substance use involving stimulants, or patients who can’t commit to telling every prescriber they are on an MAOI.

Put it in the sequence where it belongs. Many PMHNPs reach first for augmentation, ketamine and esketamine, or newer options like pramipexole for treatment-resistant depression. The patch is a reasonable next step alongside those, especially when cost or access to an REMS site is a barrier.

“New PMHNPs often treat MAOIs like a museum piece. They aren’t. The patch is a real tool for the patient who has already been through four medications and is losing hope. What it asks of you is discipline: a clean medication list, a written washout plan, and a patient who knows exactly what not to take.”

Lindsay Hill, DNP, PMHNP-BC

The Switch: Washout Timelines That Prevent Disasters

Serotonin syndrome during a switch is the most preventable serious harm in this protocol. The label is specific about the timing, and it applies in both directions.

Coming off another antidepressant

• Most SSRIs, SNRIs, and other serotonergic drugs: stop them and wait about 1 week (4 to 5 half-lives) before the first patch.
• Fluoxetine: wait at least 5 weeks after the last dose. Norfluoxetine lingers.
• Other long half-life drugs: calculate 4 to 5 half-lives for each serotonergic agent on the list, including pain medications.

Taper the old drug first, using a slow plan like the one in our hyperbolic antidepressant tapering protocol for patients who have had discontinuation symptoms before. The washout clock starts after the last dose, not when the taper begins.

Coming off the patch

After the last patch comes off, wait at least 2 weeks before starting any drug the label contraindicates. That includes switching back to an SSRI or SNRI, adding tramadol, or starting carbamazepine.

The contraindication list to memorize

The label lists SSRIs, SNRIs, clomipramine, imipramine, meperidine, tramadol, methadone, pentazocine, propoxyphene, dextromethorphan, and carbamazepine, among others. Read the full list in the label before every start. Our guide to psychiatric medication interactions every PMHNP should have memorized covers the serotonin syndrome mechanics. A printed reference like the free PMHNP prescribing cheat sheet helps when a pharmacist calls mid-session.

Write the dates into the chart and hand the patient a printed timeline: last dose of the old drug, first patch date, and the 2-week rule if they ever stop.

Dosing, Diet, and Monitoring Week by Week

The label’s starting dose and target dose are the same: 6 mg/24 hours. If you raise it, go up 3 mg at a time, at least 2 weeks apart, to a maximum of 12 mg/24 hours. For adults 65 and older, the recommended dose is 6 mg.

A practical schedule

• Day 0: washout confirmed, baseline sitting and standing blood pressure, PHQ-9, full medication reconciliation including over-the-counter and supplements.
• Week 2: skin check, sleep check, orthostatic vitals, suicidality screen.
• Weeks 4 to 6: judge response. Partial response and good tolerance may justify a step to 9 mg.
• Every visit after that: vitals, skin, mood scale, and a fresh medication list.

When the diet comes back

At 9 or 12 mg, patients must avoid tyramine-rich foods starting the first day at the higher dose. They keep avoiding them for 2 weeks after dropping back to 6 mg or stopping. The label’s examples include aged cheeses, cured and fermented meats such as salami, pickled herring, broad bean pods, unpasteurized tap beer, concentrated yeast extract, sauerkraut, and soy products.

Side effects to expect

• Application site reactions: 24% vs. 12% on placebo. Rotating sites helps.
• Insomnia: 12% vs. 7%. Morning application is a common practical fix.
• Orthostatic changes: a drop of 10 mmHg or more in 9.8% vs. 6.7%. Systolic pressure of 90 or below with a 20 mmHg drop in 3.0% vs. 1.5%.
• Headache, diarrhea, dry mouth: only slightly above placebo.

Teach patients to apply the patch to dry, intact skin on the upper torso, upper thigh, or outer upper arm, to rotate sites, and to keep heating pads, hot tubs, saunas, and long sun exposure away from it.

What Most People Get Wrong

The common belief is that the patch is the “safe MAOI” because it has no diet. That gets the risk backward.

The diet was never the biggest danger at 6 mg. The real risk is the drug interaction list, and the patch changes none of it. A patient on 6 mg who picks up a dextromethorphan cough syrup, gets tramadol after an urgent care visit, or restarts an old sertraline bottle is in the same danger as someone on an oral MAOI.

A second mistake: assuming higher doses are needed. The label’s target dose is 6 mg. Moving to 9 mg brings back the full diet, so make that move on purpose, not by habit.

A third: thinking the risk ends when the patch comes off. MAO enzymes take time to regenerate. That is why the label requires a 2-week gap after the last patch. Patients who stop on their own and restart an SSRI the next week are a real risk, so explain this before the first prescription, not after.

The fix is a system, not memory. Flag the chart, alert the pharmacy, give the patient a wallet card naming the MAOI, and reconcile medications at every visit.

Frequently Asked Questions

The Bottom Line

The selegiline patch gives treatment-resistant patients access to a proven antidepressant class without the dietary burden at 6 mg. New real-world data suggest it beats tricyclics and is easier to tolerate than oral MAOIs, though it may fall a little short of them on effectiveness.

Its safety depends on process: clean washouts, a checked medication list, and patients who know the rules. Your next step: pull the charts of patients who have failed three or more antidepressants, and for each one write down whether the patch could be next and what washout they would need. That one exercise turns this from a drug you’ve read about into one you’re ready to prescribe.

Want help with decisions like this from people who make them every week? The Psych NP Fellowship gives early-career PMHNPs case review, protocols, and live mentorship.

This content is for educational purposes and does not replace individualized clinical judgment or supervision.